Chief Financial Officer recently sold CA$55k worth of stock Apr 17
Chief Financial Officer recently sold CA$765k worth of stock Apr 09
Quantum Biopharma Ltd. Submits Investigational New Drug Application for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis Apr 01
Quantum Biopharma Intends to Submit an Investigational New Drug Application for Lucid-MS to the U.S. Food and Drug Administration in the Coming Weeks Mar 27
Quantum Biopharma Ltd. Announces Peer-Reviewed Publication of Clinical Trial Results for Unbuzzd Mar 23
Co-Founder exercised options to buy CA$94k worth of stock. Mar 19
New major risk - Market cap size Mar 12
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) Dec 26
Quantum BioPharma Ltd. has filed a Follow-on Equity Offering in the amount of $17.243174 million. Dec 23
Quantum BioPharma Ltd. announced that it has received CAD 0.00075 million in funding from Xorax Family Trust, Fortius Research and Trading Corporation Dec 12
Quantum BioPharma Ltd. has withdrawn its Follow-on Equity Offering in the amount of $21.225 million. Dec 09
New major risk - Share price stability Nov 27
Chief Financial Officer recently sold CA$512k worth of stock Nov 24
Quantum BioPharma Ltd. has filed a Follow-on Equity Offering in the amount of $21.225 million. Nov 01
Quantum BioPharma Ltd. announced that it expects to receive CAD 0.00075 million in funding from Xorax Family Trust, Fortius Research and Trading Corporation Oct 30
Quantum Biopharma Ltd. Receives Final Reports for Two Key Studies of Its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial Oct 03
Health Canada Grants Quantum BioPharma Ltd. Product License for Its Innovative Product, Qlarity™, That Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance Sep 18
Halo Biopharma Australia Pty Ltd. Signs Agreement to Manufacture Oral Drug Formulation of Its Potential Breakthrough Drug Lucid-21-302 (Lucid-Ms) for Use in Its Upcoming Phase 2 Multiple Sclerosis Trial Aug 12
New major risk - Financial position Aug 08
Quantum Biopharma Ltd. Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients Aug 08
Quantum BioPharma Ltd., Annual General Meeting, Sep 26, 2025 Aug 07
Quantum BioPharma Ltd. Announces Positive Results of the Clinical Study Report for the Phase 1 Multiple Ascending Dose Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS) Aug 05
Huge Biopharma Australia Pty Ltd. Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom Jul 09
Quantum BioPharma Ltd. announced that it expects to receive CAD 0.0006 million in funding from Xorax Family Trust, Fortius Research and Trading Corporation Jun 29
Quantum BioPharma Ltd. Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital Jun 18
iNGENu CRO Partners with Quantum Biopharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients Jun 03
Quantum BioPharma Ltd. Receives USD 2.35 Million from A Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari May 30
Quantum Biopharma Ltd. Receives Ethics Committee Approval for Phase 2 Clinical Trial of Fsd202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome May 28
New major risk - Financial position May 15
Quantum Biopharma Ltd. Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-Ms for Multiple Sclerosis May 12
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari At the Court of Appeal for Ontario Apr 14
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis Apr 01
Quantum BioPharma Ltd. announced that it has received CAD 4.9 million in funding Mar 31
New major risk - Financial position Mar 28
Less than half of directors are independent Mar 28
Quantum Biopharma Ltd. Announces Board Changes Mar 27
Quantum Biopharma Ltd. Announces Completion of Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 Feb 26
Quantum Biopharma Ltd. Announces the Success of Unbuzzd Clinical Trial Feb 04
New major risk - Share price stability Dec 22
Quantum BioPharma Ltd. announced that it expects to receive CAD 5 million in funding Dec 05
New major risk - Financial position Nov 13
Quantum BioPharma Regains Nasdaq Listing Compliance Sep 09
Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next" Aug 30
New major risk - Financial position Aug 15
FSD Pharma Announces Share Consolidation, Part of the Company's Plan to Regain Compliance with Nasdaq Minimum Bid Price Requirement Aug 13
New major risk - Shareholder dilution Aug 09
FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia Jun 28
New major risk - Market cap size Jun 09
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication Jun 05
New major risk - Financial position May 16
FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia May 08
New minor risk - Shareholder dilution Apr 10
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd Mar 12
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis (Actrims) 2024 Forum Mar 05
FSD Pharma Inc. has filed a Follow-on Equity Offering in the amount of $11.154232 million. Feb 19
FSD Pharma Inc. Announces Board Changes Jan 30
FSD Pharma Inc. Provides an Update Regarding Its Litigation with GBB Drink Lab, Inc Jan 18
GBB Maintains Strong Position in Its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case Jan 12
FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding Dec 07
FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding Nov 29
New major risk - Financial position Nov 29
FSD Pharma Inc. Announces Change of CEO Nov 18
FSD Pharma Inc. Announces the Ontario Superior Court of Justice Has Dismissed the Motion to Set Aside the Arbitration Award to FSD Pharma Filed by Raza Bokhari Oct 05
FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis Sep 19
FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023 Aug 17
New minor risk - Shareholder dilution Aug 13
New minor risk - Shareholder dilution Aug 06
FSD Pharma Inc. Announces CEO Changes Jul 06
Raza Bokhari Files Two Additional Claims Against the FSD Pharma Seeking Relief and Monetary Damages Exceeding $30.2 Million Jun 22
FSD Pharma Inc. Announces Board Changes May 26
Founder recently bought CA$442k worth of stock Apr 13
FSD Pharma Inc. Receives Regulatory Clearance for its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate Feb 08
FSD Pharma Inc. Announces Recruiting Is Underway for the Company's Phase 2 Clinical Trial of Fsd201 for the Treatment of Chronic Pain Jan 31
FSD Pharma Inc. Announces Submission of Its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS Jan 20
FSD Pharma Inc. Submits Its Phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation Jan 18
FSD Pharma Inc. Announces Committee Appointments Jan 10
FSD Pharma Announces Changes to the Board of Directors Nov 29
Less than half of directors are independent Nov 16
FSD Pharma Inc. Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari Nov 12
FSD Pharma Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 30
FSD Pharma Inc. Receives “Study May Proceed” Letter for the Investigational New Drug Application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its Phase 2 Clinical Trial of Fsd201 Sep 07
FSD Pharma Inc. Elects Fernando Cugliari as Director Jun 28
FSD Pharma Inc. Files Investigational New Drug Application with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory Disorder and Provides Corporate Updates Jun 01
FSD Pharma Inc. Announces Dismissal of Derivative Complaint May 08
FSD Pharma Inc., Annual General Meeting, Jun 23, 2022 May 07
Founder recently bought CA$63k worth of stock Apr 27
High number of new and inexperienced directors Apr 27
FSD Pharma Inc. Appoints David Allan and John Mcgraw to the Company's Advisory Board Apr 22
Founder recently bought CA$59k worth of stock Apr 14
FSD Pharma Inc. Announces Executive Appointments Apr 07
Founder recently bought CA$54k worth of stock Feb 28
An unknown buyer entered into an agreement to acquire Cobourg Facility in Cobourg, Ontario from FSD Pharma Inc. (CNSX:HUGE) for CAD 16.5 million. Feb 26 
